Many serious diseases are very difficult to diagnose early, because they are asymptomatic. The usual consequence of this is that the disease develops undetected until it reaches a fairly late, symptomatic stage, where surgery or other treatments are less effective and morbidity and mortality rates are higher. Accordingly, there is a need for early diagnostics tools which are:

• Non- or minimally invasive
• Provide high sensitivity and specificity
• High-throughput
• Inexpensive

High-throughput diagnostic kit systems which use blood, saliva, urine or other samples of body fluids can be effective for this purpose. Such kit systems require identification of disease marker proteins or peptides that are secreted from human cells into body fluids.

DrugMode has developed a new approach to identify the diagnostic marker proteins and/or actual proteolysed peptides released into human body fluids. This approach is based on our proprietary Bioreactor and a unique very sensitive protein and peptide identification technology.

We use the following process to identify diagnostic markers:

1. Biosynthetic labelling with [¹⁴C]-amino acid mix in our Bioreactor of either normal or diseased cells or biopsies.
   
   
2. A global proteome analysis of all the synthesized proteins and peptides in the cells and biopsies.
   
   
3. The diagnostic marker proteins/peptides are identified by mass spectrometry and possible PTMs are characterized.
   
   
4. Once identified, these markers can be expressed in vitro, produced as synthetic peptides or simply purified from the patient material and antibodies can be raised against them.

We have developed and patented diagnostics markers within cancer, diabetes and organ transplant rejection.

Download PDF Presentation: DrugMode Diagnostics